Exosome vs Rejuran: What's the Difference?
If you start looking into skin regeneration and texture care, you'll keep running into two keywords: "exosome" and "Rejuran." Both are often introduced with the same phrase, "skin regeneration," so when you actually ask "what exactly is the difference between these two?", organized information is hard to come by. They are in fact different treatments in their ingredients, their regulatory classification, and their level of evidence.
Today, let's walk through how Dr. Kim Gun-woo of Cellinique, on Dosan-daero in Gangnam, distinguishes between the two treatments in consultation. Because Cellinique offers both, the guidance is framed not as "which one is better" but as "for which goal and skin condition do we consider reviewing which option together". We do not frame the comparison as one being superior to the other.
Summary in 3 lines
1. Rejuran is a tissue-repair biomaterial based on PN (polynucleotide, derived from salmon DNA) that received Korea's MFDS medical device approval in 2014 (license No. 14-825). Its evidence base is comparatively clear.
2. Exosomes are currently classified mainly as cosmetics in Korea, and no exosome product has been confirmed as approved as a drug or medical device for skin treatment (no U.S. FDA approval history can be confirmed either). It is more accurate to understand it conservatively as care that uses substances isolated from sources such as cell culture media — not as a stem-cell treatment.
3. For both treatments, the degree of change, how long it lasts, and whether it is a good fit vary widely depending on each person's skin condition, age, and lifestyle, so the same outcome cannot be guaranteed, and which option suits you is decided during a prior consultation.
1. Comparison at a Glance

First, let's lay out the differences between the two treatments in a table. The table below is general guidance to help you understand the differences in direction and classification, not a ranking of which is better. Whether a given treatment suits you is decided during a prior consultation, based on your individual conditions.
| Category | Rejuran | Exosome |
|---|---|---|
| Core ingredient | PN (polynucleotide), derived from salmon DNA | Exosomes (extracellular vesicles) isolated from sources such as cell culture media — origin and composition differ by product |
| Direction of action (as commonly described) | Said to help the skin's own regeneration and elasticity recovery within the dermal environment | Introduced as supporting skin conditioning and regeneration, but standardized clinical evidence is still limited |
| Korean regulatory classification | MFDS medical device approval (license No. 14-825, 2014, tissue-repair biomaterial) | Classified mainly as a cosmetic — no product approved as a drug or medical device for skin treatment has been confirmed |
| Overseas approval | Described within the scope of Korean approval (U.S. FDA approval status needs separate verification) | No U.S. FDA-approved exosome product (there have been cases where the FDA issued warnings) |
| Goals most commonly considered | Gradual management of the skin's own condition, such as texture and elasticity | Supporting recovery and soothing after other treatments, supporting texture and tone conditioning, etc. (consultation by goal) |
| How change is observed | Gradual observation over time; individual variation is large | Gradual observation; individual variation is large — guided conservatively given the limits of the evidence |
| How long it lasts | Hard to state uniformly (individual variation) | Hard to state uniformly (individual variation; limited evidence) |
💡 Fact-check ✓
Sources: Korea's Ministry of Food and Drug Safety (MFDS, medical device approval) · Daily Pharm reporting (regulatory classification of exosomes) · U.S. FDA (exosome approval status)
- Rejuran is a tissue-repair biomaterial based on PN (polynucleotide, derived from salmon DNA) from PharmaResearch Co., Ltd., and it received MFDS medical device approval (license No. 14-825, 2014). The approved indication is "temporary improvement of facial wrinkles in adults."
- Exosomes are classified mainly as cosmetics in Korea, and it is reported that in many cases they are therefore not subject to the MFDS's drug or medical device licensing oversight (Daily Pharm). Because no exosome product approved as a drug or medical device for skin treatment has been confirmed, this article does not assert efficacy and guides the topic conservatively.
- There is no exosome product approved by the U.S. FDA for skin-treatment purposes, and there are reported cases of the FDA issuing warnings about certain exosome products.
- Effects, the degree of change, and how long they last vary by individual.
2. What Kind of Treatment Is Rejuran?
Rejuran belongs to the skin-booster category centered on PN (polynucleotide). PN is known to be an ingredient extracted and purified from salmon DNA, and in the Cellinique consultation room it is often described not as "a treatment that only fills in moisture" but as a treatment oriented toward skin regeneration and recovery.
The biggest characteristic of Rejuran is that its regulatory position is comparatively clear. Because it is a tissue-repair biomaterial that received MFDS medical device approval, its ingredient and indication can be confirmed through the approval documentation. That said, skin regeneration is a process that unfolds over time, so it is far from a treatment that is "completed in a single session," and because how long it lasts and the degree of change vary widely with individual conditions, it is hard to state in uniform figures.
If you'd like to know more about Rejuran's own mechanism, product lines, and treatment flow, we've covered it in detail in the Complete Guide to Rejuran Healer, so please refer to it as well.
In One Line
It is a skin booster, based on salmon DNA-derived PN, that addresses a skin regeneration and recovery direction and holds MFDS medical device approval. Whether it suits you and what you can expect for longevity vary with individual conditions and are decided during a prior consultation.
3. What Kind of Treatment Is Exosome? (Starting With the Regulatory View)
Exosome refers to the very small extracellular vesicles that cells secrete. In the skin field, products and care using exosomes isolated from sources such as cell culture media are sometimes introduced in the direction of "supporting skin regeneration." But the first thing that needs to be addressed here is the regulatory classification.
At present, exosomes in the skin field in Korea are in many cases classified mainly as cosmetics, and no exosome product approved as a drug or medical device for skin treatment has been confirmed. For that reason, when Cellinique discusses exosomes, it does not assert efficacy and explains them from a conservative perspective as "supportive care for which the evidence is still being accumulated." In the U.S. as well, there is no exosome product approved by the FDA for skin-treatment purposes.
There is one more point that must be made clear. Exosomes are not "stem-cell treatment" or "stem-cell injection." They involve isolating and using substances secreted by cells (extracellular vesicles), not transplanting or injecting stem cells themselves. Some explanations lump it together under the word "stem cell," but that is not an accurate expression, and Cellinique does not guide it that way.
💡 Fact-check ✓
Sources: Daily Pharm reporting (cosmetic classification of exosomes) · U.S. FDA (exosome approval and warning status)
- According to Daily Pharm reporting, exosomes in the skin field are in some cases registered as cosmetics and therefore not subject to the MFDS's drug or medical device licensing oversight, and the MFDS's position that the manufacturing stage of cosmetics is not separately reviewed was reported alongside this.
- There is no exosome product approved by the U.S. FDA for skin or cosmetic purposes, and there are reported cases where the FDA regarded certain exosome products as unapproved drugs or biologics and issued warnings.
- Exosomes are not stem-cell treatment or stem-cell injection. They are care that isolates and uses extracellular vesicles, and they must be distinguished from treatments that inject stem cells themselves.
- Specific figures such as efficacy and how long it lasts are not asserted in this article because standardized evidence is limited (individual variation applies).
In One Line
It is supportive care that uses extracellular vesicles, classified mainly as a cosmetic in Korea. Because no product approved as a drug or medical device has been confirmed, we do not assert efficacy and guide it conservatively, and we distinguish it from stem-cell treatment.
4. How Do the Ingredients and Mechanisms Differ?

The two treatments are introduced with a similar broad direction of "skin regeneration," but their starting ingredient and their known mode of action differ.
| Item | Rejuran | Exosome |
|---|---|---|
| What the ingredient is | PN (polynucleotide) — a polymer extracted and purified from salmon DNA | Exosomes (extracellular vesicles) — isolated from sources such as cell culture media; origin and composition differ by product |
| Known direction of action | Said to help skin regeneration and elasticity recovery within the dermal environment (reports exist in the clinical literature) | Introduced as supporting skin conditioning and regeneration, but standardized clinical evidence is limited |
| Level of evidence | Comparatively accumulated, with medical device approval plus clinical literature | Varies widely by product and study; standard evidence for skin treatment is still accumulating |
That is why Cellinique does not place the two treatments on the same line and compare "which one is stronger." The realistic approach is to first understand that Rejuran is a skin booster with comparatively clear regulation and evidence, while exosomes are supportive care for which the evidence is still being accumulated, and then to consider them according to your own goal.
5. For Which Goals and Concerns Do We Consider Each Together?
"Would exosome suit my skin, or Rejuran?" This is a question we're asked a lot. At Cellinique, we look at it from the perspective of "for which goal is which direction a better fit," not "which one is more popular." The following is general guidance to aid understanding, and whether it actually suits you is decided during a prior consultation, based on your individual conditions.
When Rejuran Is Considered Together
- Those who want to manage the skin's own condition, such as texture and elasticity, over time
- Those who prefer a treatment with comparatively clear regulation and evidence
- Those considering a treatment within a long-term flow of skin quality management
When Exosome Is Considered Together
- Those considering supportive care from the angle of supporting recovery and soothing after other treatments
- Those who understand it as supportive, conditioning-type care and are fully aware of the limits of the evidence
The important thing is that these two are not substitutes for each other. When the goals differ, you might review only one, or review a combination by aligning the sequence with another treatment. That said, because the evidence for exosomes is limited, we recommend approaching it carefully on the premise of "supportive care" rather than expecting efficacy. In any case, whether it suits you is decided during a prior consultation, based on your individual conditions.
6. How Do the Safety Considerations Differ?
Both treatments are unmistakably care within the medical domain, so we cannot say "there is no risk at all." Given the nature of care that involves injection, temporary swelling, redness, bruising, and tenderness can occur, and this varies with individual recovery capacity.
Exosomes in particular can vary widely by product in origin, composition, and management standards, so it is important to confirm thoroughly during a prior consultation what is used and by what standard. Cellinique spends ample time on consultation, area design, and follow-up checks for both treatments, and for care where the evidence is limited, it clearly explains those limits before deciding together whether to proceed.
Information to Share in Advance, Common to Both Treatments
- Pregnancy or breastfeeding status (including if you are planning)
- Medications you are taking (especially anticoagulants, antiplatelet agents, and immunosuppressants)
- Allergy history (including to the anesthetic lidocaine)
- History of active infection or autoimmune disease
- Other treatments received recently (the interval and sequence may need to be adjusted)
The side-effect, emergency-response, contraindication, and infection-control standards that apply commonly to all treatments can be found on the Cellinique Treatment Safety Guide page. If you are considering these two treatments, we recommend taking a look before your treatment.
7. How Cellinique Approaches the Two Treatments
Cellinique is an anti-aging skin clinic on Dosan-daero in Gangnam-gu. Because for both treatments the injection depth, area design, and recovery flow influence the result, we place importance on consistent care by the medical team and accurate delivery of information.
That is why Dr. Kim Gun-woo personally handles everything from the prior consultation through the treatment and follow-up checks. Especially for care like exosomes, where the evidence is still being accumulated, he does not exaggerate efficacy; he first explains the regulatory classification and the limits of the evidence, then helps judge together whether it fits your goal. The standard is not "famous, so do it no matter what" but "whether it actually fits your skin and goal."
Frequently Asked Questions (FAQ)
Q1. In the end, what's the difference between exosome and Rejuran?
The biggest difference is the ingredient and the regulatory classification. Rejuran is a tissue-repair biomaterial that received MFDS medical device approval (license No. 14-825, 2014) with PN (polynucleotide, derived from salmon DNA), so its evidence is comparatively clear. Exosomes, on the other hand, are classified mainly as cosmetics in Korea, and no product approved as a drug or medical device for skin treatment has been confirmed, so we do not assert efficacy and guide it conservatively as supportive care.
Q2. Isn't exosome newer, so isn't it more effective?
Being "newer" does not in itself mean "more effective." For exosomes, standardized clinical evidence in the skin field is still being accumulated, so Cellinique does not assert efficacy and explains the limits alongside it. Rather than saying which one is superior, the realistic approach is to look together in consultation at which direction is a better fit for which goal.
Q3. Is exosome a stem-cell treatment?
No. Exosomes are care that isolates and uses the extracellular vesicles (small particles) that cells secrete; they are not stem-cell treatment or stem-cell injection that transplants or injects stem cells themselves. Some explanations lump it together under the word "stem cell," but that is not an accurate expression, so Cellinique does not guide it that way.
Q4. Can I receive both treatments together?
When the goals differ, you can review a combination by aligning the sequence. That said, it is safe to design them with intervals and sequence rather than "cramming" several treatments into the same period. Exosomes in particular, given that the evidence is limited, are approached carefully on the premise of supportive care, and if you let us know during a prior consultation about the treatments and medications you are currently receiving, we will coordinate them together.
Q5. When can I start to feel the effect, and how long does it last?
For both treatments, the guidance is to observe the change gradually over time rather than it being completed right after the procedure. The degree of change and how long it lasts tend to vary widely with each person's skin condition, age, and lifestyle, so it is hard to guarantee the same outcome or a set duration. For exosomes in particular, because standard evidence is limited, we guide it even more conservatively. We recommend being fully informed during a prior consultation about the direction you can expect.
Q6. So which one is right for me?
It depends on your skin condition, goal, and expectations. If you prefer a treatment with comparatively clear regulation and evidence, we may consider Rejuran together; if your angle is supporting recovery and conditioning after other treatments, we may consider exosomes together. That said, there is no preset "correct answer" for either, so we recommend deciding after looking together at your skin and goals at the first consultation. Even if you only want a consultation, feel free to reach us at 02-6203-3434 or via KakaoTalk.
Closing
Exosome and Rejuran are bundled together with the similar phrase "both are skin regeneration," but they are treatments that differ in ingredient, regulatory classification, and level of evidence. Rejuran is a PN-based skin booster that received MFDS medical device approval, with comparatively clear evidence; exosomes are classified mainly as cosmetics and are supportive care for which the evidence is still being accumulated. Rather than one being superior, the standard is which direction fits your goal.
At Cellinique (Dosan-daero, Gangnam), Dr. Kim Gun-woo personally handles everything from the first consultation through the treatment and follow-up checks, and for care where the evidence is limited, he clearly explains those limits before deciding together. If you'd like to know more about Rejuran, please refer to the Complete Guide to Rejuran Healer; if you'd like to know more about exosomes, refer to the Complete Guide to Exosome Treatment; and the common safety standards can be found in the Cellinique Treatment Safety Guide.
Please note
- Individual variation: Results, longevity, and suitability vary with each person's skin condition, age, and lifestyle, and the same outcome cannot be guaranteed.
- Possibility of side effects: Treatments carry the possibility of side effects such as temporary erythema and swelling, and contraindications may apply, so these are confirmed during a prior consultation.
✅ Fact-check completion report
The medical and regulatory information in this article was verified against the following sources:
1. Korea's Ministry of Food and Drug Safety (MFDS) — Rejuran medical device approval (license No. 14-825, 2014, tissue-repair biomaterial, PharmaResearch Co., Ltd.), indication "temporary improvement of facial wrinkles in adults" · nedrug.mfds.go.kr
2. Daily Pharm reporting — cosmetic classification of exosomes in the skin field and whether they are subject to the MFDS's drug or medical device licensing oversight · dailypharm.com
3. U.S. FDA — no exosome product approved for skin or cosmetic purposes, and cases of warnings issued for certain exosome products · fda.govKey items verified: ✓ Rejuran ingredient (PN, derived from salmon DNA), MFDS medical device approval, and indication ✓ exosome cosmetic classification in Korea and the absence of confirmed drug/medical device approved products ✓ exosomes not approved by the U.S. FDA and warning cases ✓ the distinction that exosome ≠ stem-cell treatment ✓ individual variation and side effects stated. Because standard evidence for exosome efficacy and longevity is limited, these were described conservatively and not asserted. (Details of origin and composition by exosome product, and Rejuran's U.S. FDA approval status, are not asserted until verified directly against primary databases — FACTCHECK TODO.)
Medical disclaimer
This content is intended to provide general health information; individual diagnosis, treatment suitability, and expected effects must be decided through a prior consultation with a specialist. Every medical treatment carries individual variation and the possibility of side effects.
Cellinique consultation and booking
2F and B1, Yeonseung Building, 228 Dosan-daero, Gangnam-gu, Seoul
Phone 02-6203-3434
Hours Mon–Fri 10:00-19:00 / last Saturday of each month 10:00-16:30



